UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β

Investigational new drugs, 2018-12, Vol.36 (6), p.1103-1109

2018

Volltextzugriff (PDF)

Challenges and perspective of drug repurposing strategies in early phase clinical trials

Oncoscience, 2015, Vol.2 (6), p.576-580

2015

Volltextzugriff (PDF)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

Oncoscience, 2016, Vol.3 (5-6), p.164-172

2016

Volltextzugriff (PDF)

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

Cancer research communications, 2024-10, Vol.4 (10), p.2823-2834

2024

Volltextzugriff (PDF)

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer

American Society of Clinical Oncology educational book, 2018-05, Vol.38 (38), p.65-77

2018

Volltextzugriff (PDF)

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

Seminars in oncology, 2002, Vol.29 (3), p.4-10

2002

Volltextzugriff (PDF)

A Phase I/II Trial of Trastuzumab and Gefitinib in Patients with Metastatic Breast Cancer That Overexpresses HER2/ neu (ErbB-2)

Clinical breast cancer, 2003-06, Vol.4 (2), p.142-145

2003

Volltextzugriff (PDF)

Abstract PR01: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry

Cancer research (Chicago, Ill.), 2020-11, Vol.80 (21_Supplement), p.PR01-PR01

2020

Volltextzugriff (PDF)

Abstract 1513: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1513-1513

2020

Volltextzugriff (PDF)

Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12111-e12111

2019

Volltextzugriff (PDF)

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1105-1105

2023

Volltextzugriff (PDF)

Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-05-05

2015

Volltextzugriff (PDF)

Abstract 4626: A TRIM24-like mutational signature predicts worse relapse-free survival (RFS) and overall survival (OS) in patients (pts) with metaplastic breast cancer (MpBC)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4626-4626

2018

Volltextzugriff (PDF)

CLO19-036: Folate Receptor alpha Expression in Metastatic Triple-Negative Breast Cancer (TNBC)

Journal of the National Comprehensive Cancer Network, 2019-03, Vol.17 (3.5), p.CLO19-036

2019

Volltextzugriff (PDF)

Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1497-1497

2020

Volltextzugriff (PDF)

Midtreatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple Negative Breast Cancer

Ultrasound in medicine & biology, 2022-03, Vol.48 (6), p.1010-1018

2022

Volltextzugriff (PDF)

Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT2-06-01-OT2-06-01

2020

Volltextzugriff (PDF)

Abstract GS4-02: Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.GS4-02-GS4-02

2020

Volltextzugriff (PDF)

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.592-592

2021

Volltextzugriff (PDF)

The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.590-590

2021

Volltextzugriff (PDF)

Abstract PD11-07: Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD11-07-PD11-07

2022

Volltextzugriff (PDF)

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.588-588

2018

Volltextzugriff (PDF)

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1016-1016

2019

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(103)
Buchkapitel
(4)

Sprache

Englisch
(107)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β

Challenges and perspective of drug repurposing strategies in early phase clinical trials

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

A Phase I/II Trial of Trastuzumab and Gefitinib in Patients with Metastatic Breast Cancer That Overexpresses HER2/ neu (ErbB-2)

Abstract PR01: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry

Abstract 1513: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry

Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer

Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients

Abstract 4626: A TRIM24-like mutational signature predicts worse relapse-free survival (RFS) and overall survival (OS) in patients (pts) with metaplastic breast cancer (MpBC)

CLO19-036: Folate Receptor alpha Expression in Metastatic Triple-Negative Breast Cancer (TNBC)

Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443)

Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer

Midtreatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple Negative Breast Cancer

Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations

Abstract GS4-02: Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC)

The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC)

Abstract PD11-07: Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results

Aktive Filter

Suchergebnisse filtern